Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
Sujit V Janardhan, Nancy S Reau Center for Liver Diseases, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA Abstract: Chronic hepatitis C virus (HCV) infection represents a global health problem that affects up to 130–...
Enregistré dans:
Auteurs principaux: | , |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2015
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/b87ffaa4cb8b4d57b149574f3fe3c7a4 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|